ADX-71149

ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu₂ receptor.^[1][2][3] It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia.^[4] It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms),^[5] but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication.^[6] As of 2015^[update], ADX-71149 is in phase II clinical trials for schizophrenia.^[4]

ADX-71149

Clinical data
ATC code	None
Identifiers
IUPAC name 1-Butyl-3-chloro-4-(4-phenylpiperidin-1-yl)-1,2-dihydropyridin-2-one
CAS Number	1127498-03-6
PubChem CID	25195461
IUPHAR/BPS	8946
ChemSpider	28424210
UNII	612BYT76F3
ChEMBL	ChEMBL3337527
CompTox Dashboard (EPA)	DTXSID401150484
Chemical and physical data
Formula	C20H25ClN2O
Molar mass	344.88 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
InChI InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3 Key:HYOGJHCDLQSAHX-UHFFFAOYSA-N

See also

• Biphenylindanone A
• Eglumegad
• LY-404,039
• LY-379,268
• LY-487,379